- Home
- LRMR
LRMR
Larimar Therapeutics Inc.
as 11-14-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BALA CYNWYD |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $19.63 | AVG Volume (30 days): | 700.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.77 - $13.68 | Next Earning Date: | 10-30-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Larimar Therapeutics Inc. News
LRMR Breaking Stock News: Dive into LRMR Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Simply Wall St.
a month ago
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
GlobeNewswire
2 months ago
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
GlobeNewswire
3 months ago
Larimar Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Simply Wall St.
4 months ago
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock
GlobeNewswire
5 months ago
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
GlobeNewswire
6 months ago
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
Compare LRMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LRMR Larimar Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.